NCT05311618

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 71 (estimated)
• Sponsor: NGM Biopharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Conditions

• Pancreatic Cancer
• Breast Cancer
• Gastric Cancer
• Non Small Cell Lung Cancer
• Cervical Cancer
• Endocervical Cancer
• Squamous Cell Carcinoma of Head and Neck
• Bladder Urothelial Cancer
• Colorectal Cancer
• Esophageal Cancer
• Ovarian Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Melanoma
• Mesothelioma
• Cholangiocarcinoma

Interventions

Type	Name	Description
DRUG	NGM438	NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
DRUG	Pembrolizumab (KEYTRUDA ®)	Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Timeline

• Start date: 2022-05-11
• Primary completion: 2025-04-01
• Completion: 2025-06-01
• First posted: 2022-04-05
• Last updated: 2024-04-01

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study